{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:33:41Z","timestamp":1789835621205,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["1UM1TR004405"],"award-info":[{"award-number":["1UM1TR004405"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018188","name":"Clinical and Translational Science Institute, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ebiom.2026.106275","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:14:33Z","timestamp":1778138073000},"page":"106275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-9021","authenticated-orcid":false,"given":"Lusi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Tholkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith L.","family":"Gunlicks-Stoessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Mroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel F.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-8980","authenticated-orcid":false,"given":"Jeffrey R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40263-017-0417-0","article-title":"Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with Major Depressive Disorder (MDD)","volume":"31","author":"Keyloun","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.mayocp.2020.03.011","article-title":"Considerations when applying pharmacogenomics to your practice","volume":"96","author":"Nicholson","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"7573","key":"10.1016\/j.ebiom.2026.106275_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106275_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s44220-025-00466-8","article-title":"Clinical implementation of pre-emptive pharmacogenomics in patients with anxiety disorders","volume":"3","author":"Pandi","year":"2025","journal-title":"Nat Mental Health"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ebiom.2026.106275_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114354","article-title":"Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder","volume":"308","author":"Parikh","year":"2022","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106275_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs","volume":"30","author":"Brouwer","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ebiom.2026.106275_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J Psychiatr Res"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106275_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106275_bib14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2026.106275_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevi\u0107","year":"2024","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.ebiom.2026.106275_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105009","article-title":"Clinical implementation of preemptive pharmacogenomics in psychiatry","volume":"101","author":"Skokou","year":"2024","journal-title":"eBioMedicine"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106275_bib17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/cts.12986","article-title":"Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial","volume":"14","author":"Papastergiou","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ebiom.2026.106275_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jad.2024.05.063","article-title":"Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: a randomized clinical trial","volume":"359","author":"Xu","year":"2024","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106275_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1503\/jpn.150205","article-title":"Why is depression more prevalent in women?","volume":"40","author":"Albert","year":"2015","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.ebiom.2026.106275_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12888-020-02919-z","article-title":"Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing","volume":"20","author":"Vest","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12911-025-02886-z","article-title":"Insights into prescribing patterns for antidepressants: an evidence-based analysis","volume":"25","author":"Min","year":"2025","journal-title":"BMC Medical Informatics and Decision Making"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106275_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23543","article-title":"CYP2D6 phenotypes and emergency department visits among patients receiving opioid treatment","volume":"8","author":"Nahid","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ebiom.2026.106275_bib23","article-title":"Real-world impact of pharmacogenomic testing on medication use and healthcare resource utilization in patients with major depressive disorder","volume":"18","author":"Del Tredici","year":"2025","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ebiom.2026.106275_bib24","first-page":"293","article-title":"Clinical data cohort quality improvement: the case of the medication data in the University of Minnesota's clinical data repository","volume":"2022","author":"Kiogou","year":"2022","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106275_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70297","article-title":"Real-world characterization of psychiatric pharmacogenomic test ordering and clinical relevance in adults and children","volume":"18","author":"Zhang","year":"2025","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13692","article-title":"Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients","volume":"17","author":"Lteif","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/gim.2016.141","article-title":"Prescription medication changes following direct-to-consumer personal genomic testing: findings from the impact of personal genomics (PGen) study","volume":"19","author":"Carere","year":"2017","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106275_bib29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/da.22742","article-title":"Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: a propensity-score matched study","volume":"35","author":"Perlis","year":"2018","journal-title":"Depress Anxiety"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106275_bib30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2307\/2531734","article-title":"Models for longitudinal data: a generalized estimating equation approach","volume":"44","author":"Zeger","year":"1988","journal-title":"Biometrics"},{"issue":"i02","key":"10.1016\/j.ebiom.2026.106275_bib31","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2005","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.ebiom.2026.106275_bib32","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.ebiom.2026.106275_bib33","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106275_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpt.2387","article-title":"Pharmacogenomic clinical decision support: a review, how-to guide, and future vision","volume":"112","author":"Wake","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.636","article-title":"IGNITE network: response of patients to genomic medicine interventions","volume":"7","author":"Orlando","year":"2019","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106275_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101308","article-title":"Trends in and predictors of patient pharmacogenomic test uptake in a national health care system","volume":"27","author":"Silva","year":"2025","journal-title":"Genetics in Medicine"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jagp.2021.09.013","article-title":"Perspectives on the clinical use of pharmacogenetic testing in late-life mental healthcare: a survey of the American association of geriatric psychiatry membership","volume":"30","author":"Bousman","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106275_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.japh.2018.02.011","article-title":"Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE)","volume":"58","author":"Bain","year":"2018","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106275_bib40","first-page":"40","article-title":"Pharmacogenomic testing in child and adolescent psychiatry: an evidence-based review","volume":"48","author":"Wehry","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106275_bib41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106275_bib42","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1176\/appi.ajp.2007.06101757","article-title":"Effect of age at onset on the course of major depressive disorder","volume":"164","author":"Zisook","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ebiom.2026.106275_bib43","first-page":"273","article-title":"Pharmacogenomic testing in pediatrics: navigating the ethical, social, and legal challenges","volume":"12","author":"Haga","year":"2019","journal-title":"Pharmgenomics Pers Med"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106275_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/cap.2019.0017","article-title":"Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders","volume":"29","author":"Poweleit","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.ebiom.2026.106275_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2019.00099","article-title":"Influence of CYP2C19 metabolizer status on escitalopram\/citalopram tolerability and response in youth with anxiety and depressive disorders","volume":"10","author":"Aldrich","year":"2019","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106275_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jama.2020.25473","article-title":"Race and pharmacogenomics-personalized medicine or misguided practice?","volume":"325","author":"Goodman","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2026.106275_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1085994","article-title":"Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved","volume":"13","author":"Gawronski","year":"2023","journal-title":"Front Genet"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106275_bib50","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/cpt.3617","article-title":"A national study among diverse US populations of exposure to prescription medications with evidence-based pharmacogenomic information","volume":"117","author":"Saulsberry","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106275_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/clpt.2011.306","article-title":"Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey","volume":"91","author":"Stanek","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106275_bib52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMsa1507092","article-title":"Genetic misdiagnoses and the potential for health disparities","volume":"375","author":"Manrai","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106275_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.657985","article-title":"Pharmacogenetics in psychiatry: perceived value and opinions in a Chilean sample of practitioners","volume":"12","author":"Undurraga","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106275_bib54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ijnp\/pyx097","article-title":"Worsening anxiety, irritability, insomnia, or panic predicts poorer antidepressant treatment outcomes: clinical utility and validation of the Concise Associated Symptom Tracking (CAST) scale","volume":"21","author":"Jha","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106275_bib55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/a-1183-5029","article-title":"Patients' perspectives on psychiatric pharmacogenetic testing","volume":"53","author":"Liko","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ebiom.2026.106275_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1658616","article-title":"Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder","volume":"16","author":"Hain","year":"2025","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106275_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/appi.ajp.20230657","article-title":"Pharmacogenomic clinical support tools for the treatment of depression","volume":"181","author":"Baum","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.ebiom.2026.106275_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00717","article-title":"Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment","volume":"11","author":"Boaden","year":"2020","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106275_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/pds.2145","article-title":"Off-label prescribing patterns of antidepressants in children and adolescents","volume":"21","author":"Lee","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106275_bib60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"Lam","year":"2024","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.ebiom.2026.106275_bib61","series-title":"Recommendations | Depression in adults: treatment and management | Guidance | NICE","year":"2022"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106275_bib62","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12910","article-title":"Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial","volume":"80","author":"Thase","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ebiom.2026.106275_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.712602","article-title":"Development and implementation of in-house pharmacogenomic testing program at a major academic health system","volume":"12","author":"Mroz","year":"2021","journal-title":"Front Genet"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:50:35Z","timestamp":1783122635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642600157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"alternative-id":["S235239642600157X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106275","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106275"}}